Ensysce Biosciences Inc.: Ensysce Biosciences Issues Annual Shareholder Letter
FDA Breakthrough Therapy designation received for PF614-MPAR ~~ PF614-MPAR second clinical trial initiated ~~ Lead clinical candidate identified for OUD program ~~ PF614 Phase 3 trial poised to commen ...
Ensysce Biosciences Issues Annual Shareholder Letter
FDA Breakthrough Therapy designation received for PF614-MPAR ~~ PF614-MPAR second clinical trial initiated ~~ Lead clinical candidate identified for OUD program ~~ PF614 Phase 3 trial poised to ...
The Herald Journal10 小时
FCMC encourages blood donations
The Franklin County Medical Center is looking for blood donors as there is not enough blood available for patients at this time. The hospital encourages all who can to come ...
The Livingston Enterprise17 小时
Montana Parks approves acquisition of Judith River land for 56th state park
In a unanimous vote, the Montana State Parks and Recreation Board has approved the donation of a 100-acre parcel along the ...